Show results for
Refine by
Benign Prostate Hyperplasia Articles & Analysis
18 news found
(TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment ...
TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate ...
This noninvasive MRI-guided therapy technology is customized to each patient to target prostate disease and spare healthy tissue, offering significant quality-of-life benefits. ...
The study proved superior safety due to low irreversible complications and also superior symptom relief for prostates in the range of 50 milliliters or greater. At five years, IPSS scores improved by 15.1 points in the Aquablation group and 13.2 points in TURP (p=.2764). However, for men with larger prostates greater than 50 milliliters, IPSS reduction was 3.5 ...
Aquablation therapy provides patients a safe and effective BPH treatment option, regardless of prostate size or shape. I believe Aquablation therapy is an attractive procedure for patients who have yet to seek treatment for their BPH symptoms as well as those who are not satisfied with the results from current surgical or medical options available to treat ...
Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-centre randomized controlled trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure (performed with the TULSA-PRO® system) with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and ...
FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. “Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional MRIs, and paving ...
Zenflow, Inc., a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE™ pivotal clinical trial to evaluate its Spring System. ...
Prodeon Medical, Inc., a medical device company developing a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) caused by enlarged and obstructive benign prostatic hyperplasia (BPH), today announced the availability of interim results of its EXPANDER-1 clinical study using the Urocross Expander System (previously branded ...
Study results from the Spring System from Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), were featured at the American Urological Association 2021 annual meeting. ...
TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate ...
“TULSA-PRO® is a customizable and incision-free prostate disease treatment system that minimizes the impact on men’s functional abilities and provides the highest quality of life after treatment. ...
“Profound’s exciting noninvasive therapy technology has the potential to bring significant benefit to a large number of prostate cancer patients,” said Baldev Ahluwalia, GE MR Beyond segment general manager. ...
TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate ...
TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate ...
TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate ...
Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), today announced that it has closed a $24 million Series B financing round. ...
(NASDAQ:ULGX) and Rensselaer Polytechnic Institute to develop a real-time temperature imaging system, ProUroVision™, to be utilized with Urologix’ Cooled ThermoTherapy™ treatment of benign prostatic hyperplasia (BPH) as well as potential new indications. ...